Who
Matt Zuga
CFO & Chief Business Officer
Company insider
Files Form 4 as: CFO & Chief Business Officer, Acumen Pharmaceuticals; Director and 10% owner, Elutia; Director, TELA Bio.
In numbers
- Trades disclosed
- 53
- Buys
- 1
- Sells
- 10
- Bought
- $1.1M
- Sold
- $196K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 8 Nov 2019
- Last trade
- 22 Jan 2026
- Last filed
- 23 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jan 2026filed 23 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3,1381,687 at $1.86 | filing |
| 22 Jan 2026filed 23 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3,1381,687 at $1.86 | filing |
| 21 Jan 2026filed 23 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $4,4692,473 at $1.81 | filing |
| 21 Jan 2026filed 23 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $4,4762,473 at $1.81 | filing |
| 16 Jan 2026filed 21 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —99,133 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —148,700 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —148,700 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —99,133 at $0.00 | filing |
| 8 Jan 2026filed 12 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $13K6,888 at $1.82 | filing |
| 8 Jan 2026filed 12 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $13K6,888 at $1.82 | filing |
| 7 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $8,1894,105 at $2.00 | filing |
| 7 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3,3771,700 at $1.99 | filing |
| 7 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $8,2104,105 at $2.00 | filing |
| 7 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3,3831,700 at $1.99 | filing |
| 6 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $10K5,100 at $1.97 | filing |
| 6 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $10K5,100 at $1.97 | filing |
| 5 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $7,8424,000 at $1.96 | filing |
| 5 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $7,8404,000 at $1.96 | filing |
| 29 May 2025filed 2 Jun 2025 | ELUT Elutiaoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,339 at $0.00 | filing |
| 23 Jan 2025filed 23 Jan 2025 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $50K28,902 at $1.72 | filing |
News
No headline names them, or the companies they trade most, lately.